Bastos Juliana, Machado David José de Barros, David-Neto Elias
Santa Casa de Misericórdia de Juiz de Fora, Departamento de Transplante, Juiz de Fora, MG, Brasil.
Hospital das Clínicas da Universidade de São Paulo, Departamento de Transplante, São Paulo, SP, Brasil.
J Bras Nefrol. 2022 Jul-Sep;44(3):417-422. doi: 10.1590/2175-8239-JBN-2021-0141.
Kidney transplantation (KT) is the best treatment for chronic kidney disease. In Brazil, there are currently more than 26 thousand patients on the waitlist. Kidney Paired Donation (KPD) offers an incompatible donor-recipient pair the possibility to exchange with another pair in the same situation, it is a strategy to raise the number of KT.
KPD ceased being merely an idea over 20 years ago. It currently accounts for 16.2% of living donors KT (LDKT) in the USA and 8% in Europe. The results are similar to other LDKT. It is a promising alternative especially for highly sensitized recipients, who tend to accumulate on the waitlist. KPD is not limited to developed countries, as excellent results were already published in India in 2014. In Guatemala, the first LDKT through KPD was performed in 2011. However, the practice remains limited to isolated cases in Latin America.
KPD programs with different dimensions, acceptance rules and allocation criteria are being developed and expanded worldwide to meet the demands of patients. The rise in transplantability brought about by KPD mostly meets the needs of highly sensitized patients. The Brazilian transplant program is mature enough to accept the challenge of starting its KPD program, intended primarily to benefit patients who have a low probability of receiving a transplant from a deceased donor.
肾移植(KT)是治疗慢性肾病的最佳方法。在巴西,目前有超过2.6万名患者在等待名单上。肾配对捐赠(KPD)为不相容的供体-受体对提供了与处于相同情况的另一对进行交换的可能性,这是增加肾移植数量的一种策略。
KPD在20多年前就不再仅仅是一个想法。目前,它在美国活体供体肾移植(LDKT)中占16.2%,在欧洲占8%。其结果与其他LDKT相似。对于那些往往在等待名单上积压的高度致敏受者来说,这是一个很有前景的选择。KPD并不局限于发达国家,2014年印度就已发表了出色的成果。在危地马拉,首例通过KPD进行的LDKT于2011年完成。然而,在拉丁美洲,这种做法仍仅限于个别案例。
全球正在开发和扩展具有不同规模、接受规则和分配标准的KPD项目,以满足患者的需求。KPD带来的移植可能性的增加主要满足了高度致敏患者的需求。巴西的移植项目已经足够成熟,能够接受启动其KPD项目的挑战,该项目主要旨在使从 deceased donor 接受移植可能性较低的患者受益。 (注:这里“deceased donor”不太明确准确意思,可能是“已故供体”之类,需结合更准确原文信息判断)